Vaccine Development

Only Mature RSV Envelope Elicits Neutralizing Abs

Published in Vaccine Weekly, June 14th, 1999

Subunit vaccines for respiratory syncytial virus (RSV) must use the mature form of the immunodominant protein in the viral envelope, new studies show.

RSV is the leading viral cause of major pediatric respiratory illness. A promising attenuated live-virus RSV vaccine is now in clinical trials, but development of subunit vaccines - needed to boost immunity in elderly populations and for safe vaccination of immunocompromised populations - lags behind.

Now it appears clear why a subunit vaccine has been so hard to create: RSV has evolved a means of evading the immune system. The immunodominant epitope in the viral envelope matures by going through...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1999-06-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry